» Articles » PMID: 18193033

TBL1-TBLR1 and Beta-catenin Recruit Each Other to Wnt Target-gene Promoter for Transcription Activation and Oncogenesis

Overview
Journal Nat Cell Biol
Specialty Cell Biology
Date 2008 Jan 15
PMID 18193033
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant Wnt signalling promotes oncogenesis by increasing the nuclear accumulation of beta-catenin to activate downstream target genes. However, the mechanism of beta-catenin recruitment to the Wnt target-gene promoter, a critical step for removing the co-repressor complex, is largely unknown. Here, we report that transducin beta-like protein 1 (TBL1) and its highly related family member TBLR1 were required for Wnt-beta-catenin-mediated transcription. Wnt signalling induced the interaction between beta-catenin and TBL1-TBLR1, as well as their binding to Wnt target genes. Importantly, the recruitment of TBL1-TBLR1 and beta-catenin to Wnt target-gene promoters was mutually dependent on each other. Furthermore, the depletion of TBL1-TBLR1 significantly inhibited Wnt-beta-catenin-induced gene expression and oncogenic growth in vitro and in vivo. Our results unravel two new components required for nuclear beta-catenin function, and have important implications in developing new strategies for inhibiting Wnt-beta-catenin-mediated tumorigenesis.

Citing Articles

A Putative Frizzled 7-Targeting Compound Acts as a Firefly Luciferase Inhibitor.

Kinsolving J, Gratz L, Voss J, Low B, Shorter E, Jude B J Med Chem. 2024; 67(24):22332-22341.

PMID: 39670643 PMC: 11684006. DOI: 10.1021/acs.jmedchem.4c02766.


PPM1G-mediated TBL1X mRNA splicing promotes cell migration in hepatocellular carcinoma.

Hu L, Shi X, Yuan X, Liu D, Zheng D, Li Y Cancer Sci. 2024; 116(1):67-80.

PMID: 39462759 PMC: 11711060. DOI: 10.1111/cas.16372.


Design, Synthesis, and Biological Evaluation of Selective TBL1X Degraders.

Yang R, Pray B, Alinari L, Li P, Cheng X ACS Med Chem Lett. 2024; 15(10):1699-1707.

PMID: 39411529 PMC: 11472461. DOI: 10.1021/acsmedchemlett.4c00255.


Targeted therapies in hepatocellular carcinoma: past, present, and future.

Gujarathi R, Franses J, Pillai A, Liao C Front Oncol. 2024; 14:1432423.

PMID: 39267840 PMC: 11390354. DOI: 10.3389/fonc.2024.1432423.


Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.

de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.